Gilead Sciences, Inc.
NASDAQ:GILD 10:44:13 AM EDT
Other Pre-Announcement
Gilead Sciences - QTRLY Veklury Sales Decreased 26% To $1.0 Billion
Published: 02/02/2023 21:43 GMT
Gilead Sciences, Inc. (GILD) - Q4 Earnings per Share View $1.50, Revenue View $6.64 Billion -- Refinitiv Ibes Data (analyst estimates).
Qtrly Revenue $7.4 Billion, Up 2%; Qtrly Earnings per Share $1.30; Qtrly Adjusted Earnings per Share $1.67.
Gilead Sciences Sees 2023 Total Product Sales Between $26.0 Billion And $26.5 Billion.
Gilead Sciences Sees 2023 Earnings per Share $5.30 - $5.70; Sees 2023 Adjusted Earnings per Share $6.60 - $7.00.
FY2023 Earnings per Share View $6.73, Revenue View $25.76 Billion -- Refinitiv Ibes Data (analyst estimates).
Gilead Sciences Sees 2023 Total Veklury Sales of About $2.0 Billion to Be Highly Variable.
Gilead Sciences - Total Q4 2022 Product Sales Increased 2% to $7.3 Billion.
Gilead Sciences - Qtrly Veklury Sales Decreased 26% to $1.0 Billion.
Qtrly Revenue $7.4 Billion, Up 2%; Qtrly Earnings per Share $1.30; Qtrly Adjusted Earnings per Share $1.67.
Gilead Sciences Sees 2023 Total Product Sales Between $26.0 Billion And $26.5 Billion.
Gilead Sciences Sees 2023 Earnings per Share $5.30 - $5.70; Sees 2023 Adjusted Earnings per Share $6.60 - $7.00.
FY2023 Earnings per Share View $6.73, Revenue View $25.76 Billion -- Refinitiv Ibes Data (analyst estimates).
Gilead Sciences Sees 2023 Total Veklury Sales of About $2.0 Billion to Be Highly Variable.
Gilead Sciences - Total Q4 2022 Product Sales Increased 2% to $7.3 Billion.
Gilead Sciences - Qtrly Veklury Sales Decreased 26% to $1.0 Billion.